Functional Magnetic Resonance Imaging ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	2

6. Parkinson disease

---

Clinical trials : 2,298 /  Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05103618 (ClinicalTrials.gov)	February 1, 2022	21/10/2021	Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA	Evaluating the Physiological and Psychological Effects of a Novel Meditation Technique on Cerebral Activity Measured With Functional Magnetic Resonance Imaging(fMRI) and F-18 Fluorodopa PET Imaging	Parkinson Disease;Idiopathic Parkinson Disease	Drug: [F-18] Fluorodopa Positron Emission Tomography;Behavioral: OM Meditation	Andrew Newberg	NULL	Not yet recruiting	25 Years	N/A	All	80	Phase 2	United States
2	NCT02789020 (ClinicalTrials.gov)	December 2016	20/5/2016	Image Parkinson's Disease Progression Study	Image Parkinson's Disease Progression Study	Parkinson's Disease	Drug: Rasagiline;Other: Placebo;Device: Magnetic Resonance Imaging;Device: functional Magnetic Resonance Imaging;Other: Physical Function Performance Test	University of Florida	National Institute of Neurological Disorders and Stroke (NINDS)	Active, not recruiting	40 Years	77 Years	All	96	Phase 2	United States